Enveric Biosciences
ENVBEnveric Biosciences is a biotechnology company specializing in the development of next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders.
Table of contents
Earnings
Next report
Aug 17, 2026 (In 2 weeks)Competitors
Profile
Enveric Biosciences is a biotechnology company specializing in the development of next-generation, small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The company utilizes its proprietary discovery platform and a vast library of synthetic molecules to create non-hallucinogenic compounds designed to promote neuroplasticity. Its primary value proposition is providing fast-acting, durable treatments for depression and anxiety that can be administered in an outpatient setting.
Enveric is an early-stage drug developer focused on a niche within the psychedelic space, specifically targeting neuroplasticity without hallucinogenic side effects to enable broader clinical adoption.
Questions, answered.
- What is Enveric Biosciences's market cap?
- Enveric Biosciences (ENVB) has a market capitalization of $5.4M and trades on NASDAQ.
- Who are Enveric Biosciences's competitors?
- Enveric Biosciences's key competitors include Atai Life Sciences, ABVC BioPharma, Inc. Common Stock, Silo Pharma, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Enveric Biosciences partner with?
- Enveric Biosciences's notable partners include MycoMedica Life Sciences, PBC, Aries Science & Technology, LLC, Restoration Biologics, LLC, and others.
- What subsidiaries does Enveric Biosciences have?
- Enveric Biosciences's subsidiaries include MagicMed Industries Inc., Akos Biosciences, Inc., Enveric Biosciences Canada, Inc..
- Where is Enveric Biosciences headquartered?
- Enveric Biosciences is headquartered in United States of America and employs approximately 26 people. It has been publicly traded since 1995.